Federal and State R&D Tax Credits

Federal R&D tax credits under Section 41 of the Internal Revenue Code provide valuable tax incentives for businesses investing in research and development. To qualify, activities must meet a four-part test: (1) the activity must relate to a new or improved business component—product, process, computer software, technique, formula, or invention; (2) the activity must be technological in nature, grounded in hard sciences, engineering, computer science, or similar disciplines; (3) the activity must be intended to discover information that eliminates technical uncertainty; and (4) the process must constitute a process of experimentation—evaluating alternatives through modeling, simulation, systematic trial and error, or similar methods. Activities that don't satisfy all four parts—such as market research, routine data collection, social science research, or adaptation of existing products without technical uncertainty—do not qualify. Identifying which activities pass the Section 41 four-part test is the first and most critical step in a successful R&D credit claim, often requiring collaboration between tax professionals, engineers, and R&D project managers.

Qualified Research Expenses (QREs) are the specific cost categories eligible for inclusion in the federal R&D tax credit calculation under Section 41. The four primary QRE categories are: wages paid to employees for qualifying research activities, or for direct supervision and support of those activities—typically the largest component of QREs; supplies consumed in the conduct of qualifying research, excluding depreciable equipment and general administrative costs; contract research expenses, which are 65% of amounts paid to non-employees for qualifying research performed on the taxpayer's behalf, subject to risk-of-loss and right-of-results requirements; and computer rental costs related to qualifying research. Because wages represent the largest share of QREs, contemporaneous time-tracking records—including project-level allocations showing the percentage of each employee's time devoted to qualifying activities—are essential. The identification and documentation of QREs is a specialized undertaking that often involves cross-functional collaboration between tax, finance, engineering, and IT teams to properly capture all eligible costs in a defensible manner.

The One Big Beautiful Bill Act (OBBBA), enacted on July 4, 2025, made significant changes to federal R&D expense treatment, reversing provisions introduced by the Tax Cuts and Jobs Act of 2017. The TCJA had eliminated the ability to immediately deduct domestic R&D expenses under Section 174, instead requiring capitalization and amortization over five years (15 years for foreign R&D) for tax years beginning after December 31, 2021. This change dramatically increased the tax burden on companies with heavy R&D investment by deferring deductions over multiple years. The OBBBA restored the ability to immediately expense domestic R&D costs, providing substantial relief for innovation-driven businesses in technology, manufacturing, pharmaceuticals, and other R&D-intensive industries. Implementation guidance was issued through Rev. Proc. 2025-28, addressing transition rules and procedural requirements for affected tax years. Finance and tax professionals need to understand both the substantive changes and the procedural guidance to properly report R&D expenses and capture the benefits for applicable tax periods.

Federal R&D tax credits under Section 41 can be calculated using two methods, and taxpayers may elect which to use. Under the Regular Credit method, the credit equals 20% of current year qualified research expenses exceeding a base amount—calculated as a fixed-base percentage of average gross receipts for the preceding four years. This method can yield a larger credit but requires historical data and more complex computations. The Alternative Simplified Credit (ASC) method calculates the credit as 14% of current year QREs exceeding 50% of the average QREs for the prior three tax years; if no QREs exist in any of the prior three years, the credit is 6% of current year QREs. The ASC method is simpler and often preferred by companies with limited historical data. Taxpayers may also elect a reduced regular credit of 6.5% in lieu of reducing deductions under Section 280C, which can be advantageous depending on tax position. Unused R&D credits can be carried back one year and carried forward up to 20 years, making them a long-term tax planning asset.

Most U.S. states with income taxes offer their own R&D tax credit programs that provide additional incentives beyond the federal Section 41 credit. State credits vary significantly in their definitions of qualifying activities, credit rates, calculation methodologies, and carryforward periods—but they generally conform to or build upon the federal framework. States like California, New York, and Texas offer particularly valuable R&D credit programs. State credits are calculated separately from the federal credit and reported on state tax returns, allowing businesses to stack a federal and one or more state credits on the same qualifying expenditures. One important coordination point: when claiming the federal R&D credit, businesses may need to reduce their federal Section 174 deduction by the credit amount (unless making the Section 280C reduced credit election)—and some states have analogous adjustments. Companies with operations in multiple states—particularly in technology, manufacturing, agriculture, and life sciences—should conduct a multi-state R&D credit analysis to capture the full scope of available innovation-related tax incentives at both the federal and state level.